Update in Endocrinology
Authors: L Wartofsky
Journal: Annals of Internal Medicine (2001)

Updates from the Annual Session16 October 2001Update in EndocrinologyLeonard Wartofsky, MDLeonard Wartofsky, MDFrom Washington Hospital Center, Washington, D.C.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-135-8_Part_1-200110160-00011 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail In this update, I critically examined articles selected from more than 25 peer-reviewed journals in the endocrinology and general medicine literature. Criteria for selection included the importance of the observations and their applicability to clinical practice. The articles are broadly grouped into various areas of endocrinology.Diabetes Mellitus and LipidsImprovement in Glycemic Control Reduces Risk for Complications Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321:405-12. [PMID: 10938048]The Diabetes Control and Complications Trial and the United Kingdom Prospective Diabetes Study ...References1. Robertson RP. Successful islet transplantation for patients with diabetes—fact or fantasy? [Editorial]. N Engl J Med. 2000;343:289-90. [PMID: 10911012] CrossrefMedlineGoogle Scholar2. Ganz DA, Kuntz KM, Jacobson GA, Avorn J. Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction. Ann Intern Med. 2000;132:780-7. [PMID: 10819700] LinkGoogle Scholar3. Danese MD, Ladenson PW, Meinert CL, Powe NR. Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. J Clin Endocrinol Metab. 2000;85:2993-3001. [PMID: 10999775] MedlineGoogle Scholar4. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med. 2000;132:270-8. [PMID: 10681281] LinkGoogle Scholar5. Kumeda Y, Inaba M, Tahara H, Kurioka Y, Ishikawa T, Morii H, et al . Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism. J Clin Endocrinol Metab. 2000;85:4157-61. [PMID: 11095447] MedlineGoogle Scholar6. Wartofsky L. Levothyroxine therapy and osteoporosis. An end to the controversy? Arch Intern Med. 1995;155:1130-1. [PMID: 7763118] CrossrefMedlineGoogle Scholar7. Mercuro G, Panzuto MG, Bina A, Leo M, Cabula R, Petrini L, et al . Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring. J Clin Endocrinol Metab. 2000;85:159-64. [PMID: 10634380] CrossrefMedlineGoogle Scholar8. Grady D, Hulley SB. Hormones to prevent coronary disease in women: when are observational studies adequate evidence? [Editorial]. Ann Intern Med. 2000;133:999-1001. [PMID: 11119402] LinkGoogle Scholar9. . Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000;355:1295-302. [PMID: 10776741] CrossrefMedlineGoogle Scholar10. Mundy GR. Secondary osteoporosis: the potential relevance of leptin and low body weight [Editorial]. Ann Intern Med. 2000;133:828-30. [PMID: 11085846] LinkGoogle Scholar11. Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, et al . Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995;333:1437-43. [PMID: 7477143] CrossrefMedlineGoogle Scholar12. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al . Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535-41. [PMID: 8950879] CrossrefMedlineGoogle Scholar13. Tonino RP, Meunier PJ, Emkey R, Rodriguez-Portales JA, Menkes CJ, Wasnich RD, et al . Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab. 2000;85:3109-15. [PMID: 10999794] MedlineGoogle Scholar14. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, et al . Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab. 2000;85:4118-24. [PMID: 11095442] CrossrefMedlineGoogle Scholar15. Ravn P, Bidstrup M, Wasnich RD, Davis JW, McClung MR, Balske A, et al . Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. Ann Intern Med. 1999;131:935-42. [PMID: 10610644] LinkGoogle Scholar16. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, et al . Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000;343:604-10. [PMID: 10979796] CrossrefMedlineGoogle Scholar17. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al . Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized, controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA. 1999;282:1344-52. [PMID: 10527181] CrossrefMedlineGoogle Scholar18. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al . Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282:637-45. [PMID: 10517716] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Washington Hospital Center, Washington, D.C.Corresponding Author: Leonard Wartofsky, MD, Department of Medicine, Washington Hospital Center, 110 Irving Street NW, Washington, DC 20010-2975. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByDisfunções mínimas da tiróide: hipotiroidismo subclínico e hipertiroidismo subclínicoManagement of patients with thyroid disease 16 October 2001Volume 135, Issue 8_Part_1Page: 601-609KeywordsBoneBone mineral densityCalciumEstrogensMyocardial infarctionOsteoporosisThyroidThyroid-stimulating hormoneThyroxineUltrasound imaging ePublished: 16 October 2001 Issue Published: 16 October 2001 CopyrightCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...